Defence Therapeutics Explores Accum® Hydrogel for GLP-1 Delivery

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced a new project to explore the use of its Accum® technology. This technology aims to increase the half-life and efficacy of GLP-1 agonists, crucial for treating obesity and type 2 diabetes.

Obesity, which affects about 50% of the global population, presents a significant health challenge. Current GLP-1 analogs, although effective, have limitations such as gastrointestinal side effects, high costs, and the need for frequent injections. Defence aims to address these issues by enhancing the stability and distribution of GLP-1 analogs using its Accum® technology.

The global market for GLP-1 receptor agonists is growing rapidly and could surpass USD 125 billion by 2033. Defence's new formulation seeks to improve patient compliance and treatment outcomes.